IFF flavor 316 282, Paracetamol , Phenylephrine, Guaifenesin
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Upper Respiratory Infections
Conditions
Upper Respiratory Infections
Trial Timeline
Mar 1, 2012 → May 1, 2012
NCT ID
NCT01576809About IFF flavor 316 282, Paracetamol , Phenylephrine, Guaifenesin
IFF flavor 316 282, Paracetamol , Phenylephrine, Guaifenesin is a phase 3 stage product being developed by Novartis for Upper Respiratory Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT01576809. Target conditions include Upper Respiratory Infections.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01576809 | Phase 3 | Completed |
Competing Products
20 competing products in Upper Respiratory Infections